Boardroom Alpha
10-Q primary document
NMTC · Quarterly Report (Form 10-Q) · Filed May 12, 2026

Neuroone Medical Technologies Corp10-Q exhibit

ea028890701ex10-2.htm

Exhibit 10.2

 

THIRD AMENDMENT TO

 

NEUROONE MEDICAL TECHNOLOGIES CORPORTAION

 

2021 INDUCEMENT PLAN

 

The NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Plan”) is hereby amended in the following respects, effective November 9, 2023, in accordance with Section 2(b)(vi) of the Plan.

 

The first sentence of Section 3(a) of the Plan is deleted in its entirety and replaced with the following sentence:

 

“Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 274,224 shares (the “Share Reserve”).”

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer